Navigation Links
Catalyst Pharmaceutical Partners, Inc. Announces Organizational Changes and Extension of Chief Executive's Employment Agreement
Date:10/13/2009

CORAL GABLES, Fla., Oct. 13 /PRNewswire-FirstCall/ -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX) today announced two organizational changes and the extension of the term of Patrick J. McEnany's employment agreement with the Company for an additional two years.

Organizational Changes

The Company announced that Steven R. Miller, Ph.D. and Jack Weinstein will assume expanded responsibilities:

  • Dr. Miller, currently Catalyst's Vice President, Pharmaceutical Development and Project Management, will assume additional duties as Catalyst's Chief Scientific Officer; and
  • Mr. Weinstein, currently Catalyst's Vice President, Treasurer and Chief Financial Officer, will assume formal responsibility for Catalyst's business development activities.

Commenting on these organizational changes, Patrick J. McEnany, the Company's Chairman and Chief Executive Officer, said, "As we enter into a new phase of development at Catalyst, I am pleased to announce Steve and Jack's expanded roles. As a result of our license agreement with Northwestern University, we are now seeking to develop additional products. These products may be developed in several dosage forms and address expanded CNS indications, beyond addiction and obsessive-compulsive disorders, including epilepsy. As our Chief Scientific Officer, Steve will take an expanded role in all of our product development activities, and particularly on new product development and expanding our intellectual property portfolio. In addition, Jack's role in the management of the Company has now been expanded to include responsibility and oversight for our business development activities, as we seek to attract partnering opportunities for our product candidates."

Extension of Employment Agreement of Company's Chief Executive Officer

The Company also announced that the Board of Directors has extended the expiration date of Mr. McEnany's employment agreement with the Company from November 8, 2009 to November 8, 2011.

About Catalyst Pharmaceutical Partners

Catalyst Pharmaceutical Partners, Inc. is a biopharmaceutical company focused on the development and commercialization of prescription drugs targeting diseases of the central nervous system with a focus on the treatment of addiction and obsessive-compulsive disorders. The Company has obtained from Brookhaven National Laboratory an exclusive worldwide license for nine patents in the United States relating to the right to use vigabatrin to treat a wide variety of substance addictions and obsessive-compulsive disorders. Catalyst has also been granted rights to Brookhaven's vigabatrin-related foreign patents or patents pending in more than 30 countries. The Company's initial product candidate based on vigabatrin is CPP-109. CPP-109 has been granted "Fast Track" status by the U.S. Food & Drug Administration (FDA) for the treatment of cocaine addiction. This indicates that the FDA has recognized that CPP-109 is intended for the treatment of a serious or life-threatening condition for which there is no effective treatment and which demonstrates the potential to address unmet medical needs. Catalyst has also recently been granted worldwide rights to another patented drug, CPP-115, by Northwestern University. The Company intends to pursue development of CPP-115 for several indications, including stimulant addiction and epilepsy. For more information about the Company, go to www.catalystpharma.com.

This press release contains forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties, which may cause the Company's actual results in future periods to differ materially from forecasted results. A number of factors, including those described in the Company's filings with the U.S. Securities and Exchange Commission (SEC), could adversely affect the Company. Copies of the Company's filings with the SEC are available from the SEC, may be found on the Company's website or may be obtained upon request from the Company. The Company does not undertake any obligation to update the information contained herein, which speaks only as of this date.

SOURCE Catalyst Pharmaceutical Partners, Inc.


'/>"/>
SOURCE Catalyst Pharmaceutical Partners, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Catalyst Pharmaceutical Partners, Inc. Announces the Closing of $3.97 Million Registered Direct Offering
2. Sigma-Aldrich(R) Partners With Flow Chemistry Leader ThalesNano to Provide CatCart(R) Catalyst Products for Rapidly Growing Market
3. Catalyst Pharmaceutical Partners, Inc. To Raise $3.97 Million In Registered Direct Offering
4. Catalyst Pharmaceutical Partners Continues Clinical Development of CPP-109 For The Treatment of Cocaine and Methamphetamine Addiction
5. Catalyst Pharmaceutical Partners Announces Top-Line Results of CPP-109 Phase II Trial for Cocaine Addiction
6. Catalyst Reaches Enrollment Target for its U.S. Phase II Cocaine Trial
7. Catalyst Pharmaceutical Partners Announces Publication of Animal Data Demonstrating Vigabatrin Effective for Weight Loss
8. Catalyst Pharmaceutical Partners, Inc. Begins Enrollment for U.S. Phase II Clinical Trial of CPP-109 in Patients with Methamphetamine Addiction
9. Catalyst Biosciences Selects Drug Development Candidate in Factor VIIa Program for Hemophilia
10. Catalyst Pharmaceutical Partners Reports Fourth Quarter and Year-End 2007 Financial Results
11. Catalyst Pharmaceutical Partners Begins Enrollment for Its U.S. Phase II Clinical Trial of CPP-109 in Patients with Cocaine Addiction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/5/2017)... OMAHA, Neb. , June 5, 2017 /PRNewswire/ ... chair in the United States ... chair that helps a fallen person up to an ... is easily assembled and operated by one assistant and ... hand. It is simple enough that a child can ...
(Date:6/1/2017)... Pa. , June 1, 2017 Nutriceutical ... and Veterinarian Recommended Solutions (VRS), and KD Pharma Group ... in Nutriceutical Holdings by KD Pharma Group. KD Pharma ... with the option to acquire the entire company. ... in KD. They are committed to growing the NH ...
(Date:5/30/2017)... Israel , May 30, 2017 Therapix ... pharmaceutical Company specializing in the development of cannabinoid-based ... present a company overview at three upcoming scientific ... 7th Annual LD Micro Invitational: ... Date:                     ...
Breaking Medicine Technology:
(Date:6/28/2017)... ... June 28, 2017 , ... ... and the surrounding regions access to insurance assistance and financial planning services, is ... Ministries to assist families in the region facing financial crisis. , Matthew 25: ...
(Date:6/27/2017)... IL (PRWEB) , ... June 27, 2017 , ... ... considering a cosmetic treatment, according to survey data released today by the ... on Cosmetic Dermatologic Procedures indicates the percentage of consumers considering a cosmetic ...
(Date:6/27/2017)... ... June 27, 2017 , ... The Congressional Budget Office ... repeal and replace the 2010 Patient Protection and Affordable Care Act (ACA), would result ... would be expected under current law. , More than 20 million Americans have gained ...
(Date:6/27/2017)... ... , ... Two residents from the Gardant-managed assisted living and memory care communities ... lawmakers to protect Medicaid funding. , The video, which was produced by the American ... Chuck and Cathy Schwarz, a couple who is still able to see each other ...
(Date:6/27/2017)... ... June 27, 2017 , ... Drs. Gregory Toback and Marianne ... Mystic, CT. Covering the process and maintenance strategies of gum grafting and dental ... procedures. Drs. Toback and Urbanski practice as experienced periodontists in New ...
Breaking Medicine News(10 mins):